Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for nifedipine
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nifedipine or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on nifedipine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Nifedipine alone or combined with sildenafil citrate for management of threatened preterm labour: a randomised trial To study the tocolytic action of nifedipine combined with sildenafil citrate (SC) and if the combination is superior to nifedipine alone in inhibiting threatened preterm labour (PTL).Prospective randomised study.An Egyptian university hospital.Women with threatened PTL who received either nifedipine with SC or nifedipine alone.Patients were randomly allocated to receive either (1 (...) ) nifedipine 20 mg orally (stat dose), followed by 10 mg orally every 6-8 hours at the same time as vaginal administration of SC (25 mg at 8-hourly intervals) or (2) nifedipine alone. Medications were continued for 48-72 hours.The percentage of women who remained undelivered during hospitalisation.From January 2015 to November 2016, 239 women were randomised. The baseline characteristics of participants were similar. Nifedipine combined with SC was associated with more women remaining undelivered (81.8
Cardiogenic Shock after Nifedipine Administration in a Pregnant Patient: A Case Report and Review of the Literature We present a case of a 21-year-old Caucasian woman at 27 weeks of pregnancy who was admitted to the obstetric department for pre-term labor. She received 10 mg of nifedipine 4 times in 1 h, according to the internal protocol. Shortly after, she brutally deteriorated with pulmonary edema and hypoxemia requiring transfer to the intensive care unit (ICU) for mechanical ventilation (...) . She finally improved and was successfully extubated after undergoing a percutaneous valvuloplasty of the mitral valve. This case illustrates a severe cardiogenic shock after administration of nifedipine for premature labor in a context of unknown rheumatic mitral stenosis. Nifedipine induces a reflex tachycardia that reduces the diastolic period and thereby precipitates pulmonary edema in case of mitral stenosis. This case emphasizes the fact that this drug may be severely harmful and should never
Nifedipine Top results for nifedipine - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for nifedipine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you
Hydralazine vs nifedipine for acute hypertensive emergency in pregnancy: a randomized controlled trial There is a paucity of good quality evidence regarding the best therapeutic option for acute control of blood pressure during acute hypertensive emergency of pregnancy.We sought to compare the efficacy of intravenously administered hydralazine and oral nifedipine for acute blood pressure control in acute hypertensive emergency of pregnancy.In this double-blind, randomized, controlled trial (...) , pregnant women (≥24 weeks period of gestation) with sustained increase in systolic blood pressure of ≥160 mm Hg or diastolic blood pressure of ≥110 mm Hg were randomized to receive intravenous hydralazine injection in doses of 5, 10, 10, and 10 mg and a placebo tablet or oral nifedipine (10 mg tablet up to 4 doses) and intravenous saline injection every 20 minutes until the target blood pressure of 150 mm Hg systolic and ≤100 mm Hg diastolic was achieved. Crossover treatment was administered
Effect of maintenance tocolysis with nifedipine in threatened preterm labor on perinatal outcomes: a randomized controlled trial. In threatened preterm labor, maintenance tocolysis with nifedipine, after an initial course of tocolysis and corticosteroids for 48 hours, may improve perinatal outcome.To determine whether maintenance tocolysis with nifedipine will reduce adverse perinatal outcomes due to premature birth.APOSTEL-II (Assessment of Perinatal Outcome with Sustained Tocolysis in Early (...) to maintenance tocolysis with nifedipine orally (80 mg/d; n = 201) or placebo (n = 205) for 12 days. Assigned treatment was masked from investigators, participants, clinicians, and research nurses.Primary outcome was a composite of adverse perinatal outcomes (perinatal death, chronic lung disease, neonatal sepsis, intraventricular hemorrhage >grade 2, periventricular leukomalacia >grade 1, or necrotizing enterocolitis). Analyses were completed on an intention-to-treat basis.Mean (SD) gestational age
Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial To compare oral nifedipine with intravenous labetalol in their rapidity to control hypertensive emergencies of pregnancy.A double-blind randomised trial.A university hospital in Malaysia.Pregnant women with severe gestational hypertension≥160/110 mmHg who required immediate treatment.Patients were randomised to receive nifedipine (10 mg tablet, orally, up (...) range, IQR 22.5-67.5 minutes) versus 45 minutes (IQR 30-60 minutes) for nifedipine and labetalol, respectively (P=0.59). Repeated measures analysis of variance indicated that in the first hour both systolic (F=87.6, P<0.001) and diastolic (F=55.8, P<0.001) blood pressure significantly decreased, but there was no difference between the nifedipine and labetalol groups for both systolic (F=0.12, P=0.74) and diastolic (F=0.92, P=0.34) blood pressure trends over time. Crossover treatment was required
Nifedipine in the management of preterm labor: a systematic review and metaanalysis Nifedipine in the management of preterm labor: a systematic review and metaanalysis Nifedipine in the management of preterm labor: a systematic review and metaanalysis Conde-Agudelo A, Romero R, Kusanovic JP CRD summary The review concluded that nifedipine appeared to be a more effective tocolytic agent than beta 2 -adrenergic-receptor agonists and better tolerated compared with beta 2 -adrenergic-receptor (...) agonists and magnesium sulfate in women with preterm labour. The review was generally well conducted, but the authors’ conclusions regarding magnesium sulphate may be too strong given the small number of trials included in the analyses. Authors' objectives To determine the efficacy and safety of nifedipine as a tocolytic agent in women with preterm labour. Searching MEDLINE, EMBASE, LILACS, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, five registers of ongoing
Effectiveness of nifedipine tocolysis to facilitate external cephalic version: a systematic review The success rates of external cephalic version (ECV) are improved with the use of betamimetic tocolytics, but these drugs are associated with maternal side effects.To critically evaluate the effectiveness and advantages, if any, of nifedipine as a tocolytic for ECV.We searched PubMed, OVID [Medline, all evidence-based medicine (EBM) reviews], Embase, the Cochrane clinical trials register (...) and references therein.Randomised trials comparing nifedipine with placebo or another tocolytic agent among women with a singleton, term breech or transverse presentation.Two reviewers evaluated search results and extracted data from eligible studies using a standard data extraction form. Primary outcomes were success rates of ECV and cephalic presentation at delivery. Pooled relative risks and 95% confidence intervals were calculated for comparable studies, and where similar outcomes were assessed.Three
Nifedipine in the management of preterm labor: a systematic review and metaanalysis To determine the efficacy and safety of nifedipine as a tocolytic agent in women with preterm labor.A systematic review and metaanalysis of randomized controlled trials.Twenty-six trials (2179 women) were included. Nifedipine was associated with a significant reduction in the risk of delivery within 7 days of initiation of treatment and before 34 weeks' gestation, respiratory distress syndrome, necrotizing (...) enterocolitis, intraventricular hemorrhage, neonatal jaundice, and admission to the neonatal intensive care unit when compared with β₂-adrenergic-receptor agonists. There was no difference between nifedipine and magnesium sulfate in tocolytic efficacy. Nifedipine was associated with significantly fewer maternal adverse events than β₂-adrenergic-receptor agonists and magnesium sulfate. Maintenance nifedipine tocolysis was ineffective in prolonging gestation or improving neonatal outcomes when compared
Nifedipine as a uterine relaxant for external cephalic version: a randomized controlled trial To estimate the effectiveness of nifedipine as a uterine relaxant during external cephalic version to correct breech presentation.In this randomized, double-blind, placebo-controlled trial, women with a singleton fetus in breech presentation and a gestational age of 36 weeks or more were eligible for enrollment. Participating women received two doses of either nifedipine 10 mg or placebo, 30 and 15 (...) no significant difference in external cephalic version success rates between treatment (42%) and control group (37%) (relative risk 1.1, 95%; 95% confidence interval 0.85-1.5). The cesarean delivery rate was 51% in the treatment group and 46% in the control group (relative risk 1.1, 95% confidence interval 0.88-1.4).Nifedipine did not significantly improve the success of external cephalic version. Future use of nifedipine to improve the outcome of external cephalic version should be limited to large clinical
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Calcium antagonists are widely prescribed for angina pectoris but their effect on clinical outcome is controversial. We aimed to investigate the effect of the calcium antagonist nifedipine on long-term outcome in patients with stable angina pectoris.We randomly assigned 3825 patients with treated stable symptomatic coronary (...) disease to double-blind addition of nifedipine GITS (gastrointestinal therapeutic system) 60 mg once daily and 3840 to placebo. The primary endpoint was the combination of death, acute myocardial infarction, refractory angina, new overt heart failure, debilitating stroke, and peripheral revascularisation. Mean follow-up was 4.9 years (SD 1.1). Analysis was by intention to treat.310 patients allocated nifedipine died (1.64 per 100 patient-years) compared with 291 people allocated placebo (1.53 per 100
Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. Tardive dyskinesia (TD) is a potentially disfiguring movement disorder of the orofacial region often caused by use of neuroleptic drugs. A wide range of strategies have been used to help manage TD and, for those who are unable to have their antipsychotic medication stopped or substantially changed, the calcium-channel blocking group of drugs (diltiazem, nifedipine, nimodipine, verapamil) has been
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). The efficacy of antihypertensive drugs newer than diuretics and beta-blockers has not been established. We compared the effects of the calcium-channel blocker nifedipine once daily with the diuretic combination co-amilozide on cardiovascular mortality and morbidity (...) in high-risk patients with hypertension.We did a prospective, randomised, double-blind trial in Europe and Israel in 6321 patients aged 55-80 years with hypertension (blood pressure > or = 150/95 mm Hg, or > or = 160 mm Hg systolic). Patients had at least one additional cardiovascular risk factor. We randomly assigned patients nifedipine 30 mg in a long-acting gastrointestinal-transport-system (GITS) formulation (n=3157), or co-amilozide (hydrochlorothiazide 25 mg [corrected] plus amiloride 2.5 mg; n
Safety of nifedipine in angina pectoris: a meta-analysis Safety of nifedipine in angina pectoris: a meta-analysis Safety of nifedipine in angina pectoris: a meta-analysis Stason W B, Schmid C H, Niedzwiecki D, Whiting G W, Caubet J F, Cory D, Luo D, Ross S D, Chalmers T C Authors' objectives To compare cardiovascular event rates in patients with stable angina receiving nifedipine as monotherapy or combination therapy and in active drug controls. Searching MEDLARS (1966 to August 1995 (...) ) was searched using the exploded MESH term "myocardial ischemia" and "nifedipine" as a textword. Studies published in English, French, Italian, German and Spanish languages were included. CD-ROM Current Contents and bibliographies of retrieved articles were also searched. Study selection Study designs of evaluations included in the review Published randomised controlled trials (RCTs) that enrolled a minimum of 10 patients. Specific interventions included in the review Any nifedipine formulation, either
Nifedipine versus ritodrine for suppression of preterm labor: a meta-analysis Nifedipine versus ritodrine for suppression of preterm labor: a meta-analysis Nifedipine versus ritodrine for suppression of preterm labor: a meta-analysis Oei S G, Mol B W, de Kleine M J, Brolmann H A Authors' objectives To assess the effectiveness of nifedipine and ritodrine in the suppression of pre-term labour. Searching MEDLINE was searched from January 1966 to November 1998, and EMBASE from January 1980 (...) to November 1998, using the following keywords: 'nifedipine', 'ritodrine' and 'randomised'. Cross-references of selected studies were checked. A formal assessment of publication bias was not possible due to small sample sizes. Study selection Study designs of evaluations included in the review Randomised clinical trials (RCTs) were eligible. Specific interventions included in the review Direct comparisons of ritodrine and nifedipine were eligible. Ritodrine doses (where stated) ranged from an infusion
Clinical and economic outcomes of a nifedipine-to-felodipine switch program Clinical and economic outcomes of a nifedipine-to-felodipine switch program Clinical and economic outcomes of a nifedipine-to-felodipine switch program Dearing C J, Briscoe T A, Morgan S M, Block L C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Second generation dihydropyridine calcium channel blockers for the treatment of hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with hypertension switching from treatment with nifedipine to treatment with felodipine. Setting Outpatient clinic. The economic analysis was conducted in Atlanta, Georgia, USA. Dates to which data relate
Nifedipine et insuffisance coronarienne: raisons d'une controverse [Nifedipine and coronary heart disease: reasons for controversy] Nifedipine et insuffisance coronarienne: raisons d'une controverse [Nifedipine and coronary heart disease: reasons for controversy] Nifedipine et insuffisance coronarienne: raisons d'une controverse [Nifedipine and coronary heart disease: reasons for controversy] Lievre M, Cucherat M Authors' objectives The authors state that their objective is to assess criticisms (...) levied at a previously published meta-analysis of nifedipine for coronary heart disease (Furberg et al 1995 - see Other Publications of Related Interest). However, they also appear to have attempted to extend the review, in order to provide additional data. Searching Data were used from the review by Furberg et al 1995 (see Other Publications of Related Interest). Other sources included MEDLINE (search terms and years searched not provided) and handsearching of English, French, Italian, Spanish
Safety of nifedipine in patients with hypertension: a meta-analysis Safety of nifedipine in patients with hypertension: a meta-analysis Safety of nifedipine in patients with hypertension: a meta-analysis Stason W B, Schmid C H, Niedzwiecki D, Whiting G W, Caubet J-F, Luo D, Ross S D, Chalmers T C Authors' objectives To compare cardiovascular event rates in patients with mild or moderate hypertension who received nifedipine with active drug controls. Searching MEDLARS was searched from 1966 (...) to August 1995 using the MeSH 'hypertension' and 'nifedipine' as a textword. Studies published in English, French, Italian, German or Spanish were included. Current Contents (CD-ROM), and the bibliographies of retrieved articles were also searched. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included if they had a minimum of 10 patients, were published in a peer-reviewed journal or supplement to such a journal, and reported adverse events
Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension Malik A S, Warshafsky S, Lehrman S Authors' objectives Assess the magnitude and consistency of the effect of nifedipine on reducing pulmonary artery pressure (PAP) in patients with pulmonary hypertensive disorders. Searching MEDLINE was searched from 1966 (...) to 1995 using the keywords field for the combination 'nifedipine' and 'pulmonary hypertension'. Bibliographies of retrieved articles were also reviewed. Study selection Study designs of evaluations included in the review Case series were included. Specific interventions included in the review Nifedipine (30 to more than 200 mg/day). Participants included in the review Patients with the following illnesses were included in the analysis: pulmonary hypertension secondary to chronic obstructive pulmonary
Nifedipine: dose-related increase in mortality in patients with coronary heart disease Nifedipine: dose-related increase in mortality in patients with coronary heart disease Nifedipine: dose-related increase in mortality in patients with coronary heart disease Furberg C D, Psaty B M, Meyer J V Authors' objectives To assess the effect of nifedipine dose on mortality and to review the potential mechanisms of such an effect. Searching The authors do not provide details of the sources searched (...) or the strategies used. Study selection Study designs of evaluations included in the review All published randomised controlled trials (RCTs) of nifedipine in the secondary prevention of CHD for which mortality data were available, were included. Specific interventions included in the review Nifedipine at doses of 30, 40, 50, 60, 80 and 100 mg/day, to a maximum of 120 mg. Participants included in the review Patients with coronary heart disease (CHD). Of the 16 studies included, 12 included patients